For the first time, researchers have found that a novel immunologic therapy increases survival by nearly 18 percent in men with advanced prostate cancer that no longer responds to hormone therapy.
The therapeutic cancer vaccine, called APC8015 (Provenge), is likely to become a new standard of care for patients with metastatic prostate cancer. The UCSF-led study is the first to demonstrate a survival benefit from immunologic therapies or vaccines in patients with advanced prostate cancer.
"We're very pleased with the results. A therapy that prolongs life yet avoids the side effects of other therapeutic approaches is clearly attractive to patients and physicians alike," said Eric Small, MD
, UCSF professor of medicine and urology and lead investigator of the study.
Read more at UCSF Today